Triple negative breast cancer (TNBC) is more aggressive than other breast cancer (BC) subtypes and accounts for up to 20% of all BC. Despite the poorer prognosis, there are no approved targeted treatments available and chemotherapy (chemo) remains the only choice. We examined treatment patterns and outcomes among elderly metastatic TNBC patients (pts) in routine clinical practice.
Patients were identified from the linked SEER-Medicare database (1/1/2001-12/31/2013). The analysis included TNBC de novo Stage IV pts (n = 776) and pts with distant recurrences following an initial diagnosis of Stage I-III (n = 1851). Pts were ≥66 years and continuously enrolled in Medicare Parts A/B in the year prior to diagnosis. The analysis was stratified by age
The mean age at metastatic diagnosis was 77.6 years and 1259 (48%) pts received treatment with chemo. Compared to
In this real-world analysis, 52% of elderly TNBC pts did not receive chemo following their metastatic diagnosis. Although the survival benefits of chemo were stronger in the younger cohort, the benefits of treatment were maintained among ≥70 year olds who were also less likely to receive chemo. These findings suggest opportunities exist to improve the clinical treatment of elderly TNBC pts.
Clinical trial identification
Legal entity responsible for the study
Q.D. Research, Inc
S. Satram-Hoang, K.Q. Hoang, F. Momin: Research funding to Institution from Genentech. P. Bajaj, A. Stein, P. Cortazar, C. Reyes: Genenetech employment and Roche stock ownership.